Search results
Results from the WOW.Com Content Network
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2] Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion .
In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. [1]
Nausea and vomiting are two of the most feared cancer treatment-related side-effects for people with cancer and their families. In 1983, Coates et al. found that people receiving chemotherapy ranked nausea and vomiting as the first and second most severe side-effects, respectively. [ 98 ]
Brentuximab Vedotin is an antibody-drug conjugate. Passive antibody administration has become a widely approved cancer treatment following the development of monoclonal antibody (mAb). Since these antibodies originated from mice, they were wrought with problems of immunogenetics and poor abilities to induce an immune response in the human body ...
In July 2009, the FDA updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) indicated for the treatment of metastatic colorectal cancer to include information about KRAS mutations. [14] This was the result of a study, which demonstrated lack of benefit with Panitumumab in patients who carried NRAS mutations. [6]
A painting from 1681 depicting a person affected by nausea and vomiting. Cancer and nausea are associated in about fifty percent of people affected by cancer. [1] This may be as a result of the cancer itself, or as an effect of the treatment such as chemotherapy, radiation therapy, or other medication such as opiates used for pain relief.
Another avenue for novel anti-cancer therapies is re-engineering some of the currently used conventional antibodies like trastuzumab (targeting HER2/neu), cetuximab and panitumumab (both targeting the EGF receptor), using the BiTE approach. [28] As of 2009, BiTEs against CD66e and EphA2 are being developed as well. [29]
Cetuximab is the first-line therapy for Ménétrier disease. [2] Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR), and has been shown to be effective in treating Ménétrier disease. [7] Several medications have been used in the treatment of the condition, with variable efficacy.